INT85260

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1999
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 7.08
Pain Relevance 3.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

ATPase activity (ATF7IP) nucleus (ATF7IP)
Anatomy Link Frequency
D17 3
nerve 1
ATF7IP (Homo sapiens)
Pain Link Frequency Relevance Heat
depression 396 99.96 Very High Very High Very High
Duloxetine 274 99.18 Very High Very High Very High
Dopamine 18 96.60 Very High Very High Very High
antidepressant 118 95.60 Very High Very High Very High
fluoxetine 18 92.00 High High
noradrenaline 7 91.70 High High
Pain 44 88.76 High High
Paresthesia 7 87.28 High High
headache 29 83.44 Quite High
Limbic system 3 81.92 Quite High
Disease Link Frequency Relevance Heat
Depression 656 99.96 Very High Very High Very High
Anxiety Disorder 66 99.96 Very High Very High Very High
Somatoform Disorder 2 99.64 Very High Very High Very High
Obesity 54 97.08 Very High Very High Very High
Body Weight 9 95.88 Very High Very High Very High
Manic Depressive Disorder 77 95.52 Very High Very High Very High
Recurrence 66 93.76 High High
Appetite Loss 45 91.44 High High
Vomiting 65 90.72 High High
Pain 33 88.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
SLC6A2 gene encodes a transporter, which regulates norepinephrine (noradrenaline) homeostasis and the reuptake of norepinephrine into presynaptic nerve terminals.24 SLC6A2 polymorphisms have been reported to be associated with depression25, 26 and response to antidepressants.27, 28 (v) SNPs or haplotypes in SLC6A3 (dopamine transporter or DAT1, located at 5p15.33), which encodes a transporter that is important in dopaminergic neurotransmission, were associated with risk for MDD or relative reduction of HAM-D21.
Negative_regulation (reduction) of HAM in nerve associated with dopamine, antidepressant, depression and noradrenaline
1) Confidence 0.41 Published 2009 Journal Mol Psychiatry Section Body Doc Link PMC2834349 Disease Relevance 0.52 Pain Relevance 0.41
Similarly, HAM-D scores were reduced from Baseline (M = 26.7, SD = 6.3; Range: 12 – 36) to Week 8 (M = 3.7, SD = 3.3; Range: 1 – 13).
Negative_regulation (reduced) of HAM-D
2) Confidence 0.21 Published 2004 Journal BMC Psychiatry Section Body Doc Link PMC535560 Disease Relevance 0.49 Pain Relevance 0.19
A database of 17 randomized controlled acute trials of duloxetine in adult MDD was subjected to meta-analysis with random effects modeling.38 Response rates (reduction of baseline HAM-D by ?
Negative_regulation (reduction) of HAM-D associated with duloxetine
3) Confidence 0.21 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2846146 Disease Relevance 0.22 Pain Relevance 1.01
The reduction in HAM-D scores reached statistical significance, t(1, 13) = 9.92, p < .001.
Negative_regulation (reduction) of HAM-D
4) Confidence 0.18 Published 2004 Journal BMC Psychiatry Section Body Doc Link PMC535560 Disease Relevance 0.43 Pain Relevance 0.19
50% decrease in HAM-D scores.
Negative_regulation (decrease) of HAM-D
5) Confidence 0.15 Published 2004 Journal BMC Psychiatry Section Body Doc Link PMC535560 Disease Relevance 0.31 Pain Relevance 0.16
The response rate was also 93%, with 14 of the 15 patients achieving 50% or greater reduction in HAM-D scores.
Negative_regulation (reduction) of HAM-D
6) Confidence 0.13 Published 2004 Journal BMC Psychiatry Section Body Doc Link PMC535560 Disease Relevance 0.27 Pain Relevance 0.11
The intent-to-treat response rate was 74%, with 14 of the 19 patients achieving 50% or greater reduction in HAM-D scores.


Negative_regulation (reduction) of HAM-D
7) Confidence 0.13 Published 2004 Journal BMC Psychiatry Section Body Doc Link PMC535560 Disease Relevance 0.60 Pain Relevance 0
Of completers, 14 (78%) were clinical responders by CGI and reduction in HAM-D > 50%.
Negative_regulation (reduction) of HAM-D
8) Confidence 0.08 Published 1999 Journal J Clin Psychiatry Section Body Doc Link 10584761 Disease Relevance 0.12 Pain Relevance 0
The mean Hamilton Rating Scale for Depression (HAM-D or HDRS) scores were not significantly reduced from baseline to the final visit.
Neg (not) Negative_regulation (reduced) of HAM-D associated with depression
9) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2714287 Disease Relevance 1.14 Pain Relevance 0.21
In a multi-center study, 30 depressed patients (n = 21; nonpsychotic treatment-resistant major depression, n = 4; bipolar, and n = 5 bipolar II) underwent 10 weeks of VNS after which 40% of patients reported having a significant reduction in mood-scale scores (Ham-D and MADRS).
Negative_regulation (reduction) of Ham-D associated with depression
10) Confidence 0.03 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671781 Disease Relevance 0.34 Pain Relevance 0.23
There was a significantly greater reduction in HAM-D17 from baseline for both DVS 200 mg/day (?
Negative_regulation (reduction) of HAM-D17 in D17
11) Confidence 0.03 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.09 Pain Relevance 0.09
Results from an open label, 12-month, flexible dose trial of DVS (mean > 300 mg/day) showed a steady decrease in HAM-D17 total score from baseline of approximately nine points, and statistically significant improvements from baseline in disability measures assessed by the SDS.44

Safety and tolerability

Negative_regulation (decrease) of HAM-D17 in D17
12) Confidence 0.03 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.55 Pain Relevance 0.06
In addition, in Study 5, duloxetine (80 mg/day or 120 mg/day) significantly improved both the HAM-D17 anxiety/somatization subscale and HAMA scale more than placebo (Detke et al 2004).


Negative_regulation (improved) of HAM-D17 in D17 associated with somatoform disorder, anxiety disorder and duloxetine
13) Confidence 0.02 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654630 Disease Relevance 1.38 Pain Relevance 0.51
Significant decrease in YMRS and HAM-D were observed in four patients.
Negative_regulation (decrease) of HAM-D
14) Confidence 0.02 Published 2005 Journal Ann Gen Psychiatry Section Body Doc Link PMC1088011 Disease Relevance 0.61 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox